16,792 Shares in Stryker Corporation $SYK Acquired by Covington Investment Advisors Inc.

Covington Investment Advisors Inc. bought a new stake in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 16,792 shares of the medical technology company’s stock, valued at approximately $5,287,000.

Other institutional investors have also added to or reduced their stakes in the company. Gables Capital Management Inc. purchased a new position in shares of Stryker during the 2nd quarter worth $25,000. Kilter Group LLC purchased a new stake in shares of Stryker in the 2nd quarter worth $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the 4th quarter worth $26,000. Sankala Group LLC bought a new position in Stryker in the 4th quarter worth $26,000. Finally, Compass Financial Management LLC purchased a new position in Stryker during the second quarter valued at $27,000. 77.09% of the stock is currently owned by institutional investors.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Insider Buying and Selling at Stryker

In other news, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 665,370 shares of company stock valued at $216,238,501 in the last three months. 4.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

SYK has been the subject of several recent research reports. UBS Group assumed coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target for the company. BMO Capital Markets assumed coverage on Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective for the company. Truist Financial increased their target price on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Citigroup restated a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Finally, Needham & Company LLC lowered their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Price Performance

NYSE:SYK opened at $329.86 on Monday. The business’s 50-day simple moving average is $326.99 and its two-hundred day simple moving average is $332.39. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The stock has a market cap of $126.52 billion, a PE ratio of 34.18, a P/E/G ratio of 2.10 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the prior year, the company posted $3.13 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.